

**SARDA PROTEINS LIMITED**

Reg. Office:

G-1-177(A) Matsya Industrial Area,

Alwar-301030 (Rajasthan)

CIN: L15142RJ1991PLC006353

Phone: 0144-2881392, +919413385217

E Mail:sardaproteins@yahoo.com

Website: [www.sardaproteins.com](http://www.sardaproteins.com)

**Date: 05.02.2019**

**To,  
The Manager,  
Department of Corporate Services,  
B.S.E. Ltd.,  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street, Fort, Mumbai-400001**

**(BY BSE LISTING CENTRE)**

**Sub.: Outcome of the Board Meeting held on Tuesday, 05<sup>th</sup> February, 2019 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sarda Proteins Limited, Scrip Code: 519242, Security ID: SRDAPRT.**

Respected Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Tuesday, the 05<sup>th</sup> day of February, 2019, at the registered office of the Company situated at G-1-177(A), Matsya Industrial Area, Alwar-301030 (Rajasthan) which commenced at 04:00 P.M. and concluded at 05:00 P.M., *inter-alia*, transacted the following business:

1. Approved the un-audited financial results for the quarter and nine months ended 31<sup>st</sup> December, 2018. (copy enclosed)

Further, the extract of financial results would also be published in the newspapers in compliance with regulation 47 of Listing Regulations.

2. Took on record the Limited review report on the Un-audited Financial Results for the quarter ended 31<sup>st</sup> December, 2018. (copy enclosed)
3. Took on record the statement of Investor Grievances pursuant to Regulation 13 of Listing Regulations, stating that no complaints from the investors have been received during the quarter ended on 31<sup>st</sup> December, 2018.

**TRADING WINDOW:**

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 08<sup>th</sup> February, 2019 for the Directors and Key Managerial Personnel / Designated Employees / Connected Persons of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company.

**SARDA PROTEINS LIMITED**

Reg. Office:

G-1-177(A) Matsya Industrial Area,

Alwar-301030 (Rajasthan)

CIN: L15142RJ1991PLC006353

Phone: 0144-2881392, +919413385217

E Mail:sardaproteins@yahoo.com

Website: [www.sardaproteins.com](http://www.sardaproteins.com)

You are requested to kindly take the same on record and inform all those concerned accordingly.

Thanking you,  
Yours faithfully,

**For Sarda Proteins Ltd.**

**For SARDA PROTEINS LTD.**

*Varun*

**Varun Motwani**

**Company Secretary &**

**Compliance Officer**

**Enclosures: as above**



*Khetawat Agarwal & Co.*  
*Chartered Accountants*

## Limited Review Report

### **Review Report to Sarda Proteins Limited, Alwar**


We have reviewed the accompanying statement of unaudited financial results of Sarda proteins limited, G-1-177 (A), MIA , ALWAR-301030 for the period ended 31<sup>ST</sup> December, 2018 . This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2400, *engagements to review financial statements* issued by the institute of chartered accountants of India. This standard requires that we plan and perform the review to obtain the moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclose in terms of regulation 33 of the SEBI (listing obligations and disclosures requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co  
Chartered Accountants  
FRN NO. 003960C



  
M.L. AGARWAL  
(Partner)

M. No. 072854

Place: Alwar

Dated: 05/02/2019

Office : 103, 1<sup>st</sup> Floor, City Center Ashok Circle, Alwar-301001 (Rajasthan)

Phone : Office 0144 - 2340924

Mobile : 9414215353 (ML Agarwal)

E-mail : khetawatagarwal21@gmail.com

**SARDA PROTEINS LIMITED**

Reg Off:G-1-177 (A), Matsya Industrial Area, Alwar-301030 (Rajasthan),  
Phone: 0144-2881392, E Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com  
CIN: L15142RJ1991PLC006353

**STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON DECEMBER 31, 2018**

Rs.in Lakhs

Particulars	Quarter/Three Month Ended			Nine Month Ended		Year Ended
	31.12.18	30.09.18	31.12.17	31.12.18	31.12.17	31.03.18
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	(Audited)
I. Revenue from operations	202.85	203.30	91.60	502.05	481.76	563.19
II. Other Income	0.00		0.30	2.93	1.14	2.03
III. Total Revenue (I+II)	202.85	203.30	91.90	504.98	482.90	565.22
IV. Expenses:						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Stock-in-Trade	199.85	202.60	73.24	453.92	436.53	486.96
Changes in inventories of:			0.00			
Finished Goods	0.00	0.00	0.00	0.00	0.00	0.00
Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Stock in Trade	0.00	0.00	14.87	42.82	30.73	60.80
Employee Benefit Expenses	3.38	5.38	6.94	15.02	20.39	26.99
Finance Cost	0.00	(0.01)	0.08		0.21	0.22
Depreciation and Amortisation Expenses	0.23	0.22	0.39	0.67	1.17	1.12
Other expenses	1.63	2.50	5.71	9.82	19.32	25.94
Total Expenses (IV)	205.09	210.69	101.23	522.25	508.35	602.03
V.Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	(2.24)	(7.39)	(9.33)	(17.27)	(25.45)	(36.81)
VI. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	(2.24)	(7.39)	(9.33)	(17.27)	(25.45)	(36.81)
VIII. Tax Expense:						
(1) Current Tax	0.00	0.00	0.00	0.00	(0.87)	(0.87)
(2) Deferred Tax	0.00	(3.00)	0.00	(3.00)	(3.50)	(2.86)
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	(2.24)	(4.39)	(9.33)	(14.27)	(21.08)	(33.08)
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI. Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	(2.24)	(4.39)	(9.33)	(14.27)	(21.08)	(33.08)
XIV. Other Comprehensive Income						
A (i) Items will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	(2.24)	(4.39)	(9.33)	(14.27)	(21.08)	(33.08)
XVI. Earnings per Equity Share						
(1) Basic	(0.13)	(0.25)	(0.54)	(0.83)	(1.22)	(1.92)
(2) Diluted	(0.13)	(0.25)	(0.54)	(0.83)	(1.22)	(1.92)
XVII. Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on February 5, 2019.

2. Segment reporting as defined in Accounting Standard 17 is not applicable as company have only one segment "Agro Products".  
3. There were no investor complaints pending as on 1-Jan-2019 and nor any complaints received during the quarter.

Place: Alwar

Date: 05.02.2019

On behalf of the board

D.P.Sarda (DIN: 00763377)  
Whole time Director and CFO

